CD BioGlyco has a high-end platform that provides comprehensive Technologies for HMO Production. We have the confidence to be your best partner to help you resolve problems.
There are a lot of complex parts in human milk, such as fats, Carbohydrates, vitamins, Proteins, minerals, and trace elements. At present, the major fraction is represented by carbohydrates. Carbohydrates in human milk can be divided into Lactose and more complex Oligosaccharides. Lactose is an energy source, but complex carbohydrates are not metabolized by babies. There are almost 150 different complex oligosaccharides that account for up to 1/10 of the total carbohydrate fraction. The existence of these complex carbohydrates is specific to humans. The milk of other mammals, such as domesticated dairy animals, doesn’t contain large quantities of complex oligosaccharides. The existence of these complex oligosaccharides in human milk has been already for a long time and the physiological functions of these oligosaccharides were subject to medicinal research for many decades. For some of the more abundant human milk oligosaccharides, specific functions have already been recognized.
There are three major types of HMOs in human breast milk, fucosylated HMOs, sialylated HMOs, and non-fucosylated neutral HMOs. LNO is a neutral non-fucosylated HMO. LNO contains neither Sialic Acid nor fucose. The core structure of LNO shows in Fig.1.
Fig.1 The core structure of LNO. (CD BioGlyco)
One way to obtain the same oligosaccharides found in human milk would be to purify them directly from breast milk. This approach, however, is unsuitable for commercial HMO production. Chemical synthesis can be used to produce HMOs. However, complexity, the total number of reaction steps, and the limited availability and high cost of raw materials make a chemical synthesis of HMOs prohibitively expensive for dairy and nutrition applications.
Another methodology to produce HMOs is chemoenzymatic synthesis, where glycosyltransferases are expressed recombinantly and used together with matching nucleotide-activated donor substrates and acceptors. It has been applied to generate libraries of structurally diverse HMOs for research purposes. CD BioGlyco uses microbes to produce LNO. Microbial production is a very stable and safe method. HMOs, go through many steps of purification to remove all microorganism cells and other starting ingredients, resulting in a final product that is of high purity and safe.
CD BioGlyco has a large number of experience in the production of HMOs. We will perform a verification step after production to assure that our products are of high quality and high purity. If you are interested in our services, please feel free to contact us for more detailed information.
Reference
